New York, NY -- January 7, 2021 -- InvestorsHub NewsWire -- Traders News Source, a leading independent equity research and corporate access firm focused on small cap growth companies issues new biotech stock reports and resources for timing biotech trades.

Amarin Corporation plc (NASDAQ: AMRN) only has one drug, Vascepa. It's a medication that reduces strokes and heart attacks. Some say that Vascepa is one of the most important developments in the prevention and treatment of cardiovascular disease since statins.
While Vascepa is an approved drug, sold in the USA, ten months ago an American judge (the company is based in Ireland) vacated some Amarin patents, opening the door for generic competition. AMRN is still waiting for Vascepa approval in the EU and anticipates a patent protected rollout of the product there. Estimates for peak sales in the EU are at $2.8 billion.

Three months ago, Northwest Biotherapeutics, Inc. (OTCQB: NWBO) announced that the database for the Phase III trial of DCVax®-L for Gliobastoma has been locked. The phase III trial had been ongoing for 14 years and now independent statisticians are tallying up the results. DCVax®-L is the only product of consequence for NWBO, so the company’s future rides on the clinicals results. On September 1, 2020 NWBO acquired Flaskworks, a company that has developed and automated the manufacturing of cell therapy products such as DCVax®.
There are parties on both sides of the NWBO and DCVax®-L prospects discussion with valid points to make. Investors are examining the bullish and bearish cases to determine which one best fits their investing agenda.

See Traders News Source FDA / PDUFA research resources for Biotech investors READ MORE
Copy and paste to browser may be required

CytoDyn Inc. (OTCQB: CYDY) is a late-stage biotechnology company developing Vyrologix™, a CCR5 antagonist with the potential for multiple therapeutic indications. The company has been studying the impact of Vyrologix on Covid 19 patients. Nicholas J. Agresti, M.D. has treated four patients, on ventilators, with great success and written a paper detailing the results. The paper has been accepted for publication in the Journal of Translational Autoimmunity.
Nader Pourhassan, Ph.D., President and Chief Executive Officer of CytoDyn, commented, “We are appreciative of Dr. Agresti’s work and view his publication as a validation of Vyrologix as an important potential therapeutic in the treatment of seriously ill COVID-19 patients.

Enzolytics Inc. (OTCPINK: ENZC) and BioClonetics Immunotherapeutics, Inc. entered a non-binding letter of intent to combine the two entities and pursue our joint mission to create therapeutics that are effective and affordable for the treatment of some of the most infectious and deadly diseases in the world, including HIV and the Coronavirus.
According to a December letter to shareholders:” Our new lab is being opened on the campus of Texas A&M University in the University's Institute for Preclinical Studies. Here we will expand our development capabilities for the production of additional monoclonal antibodies targeting immutable sites on the HIV and SARS-CoV-2 viruses. We have engaged an artificial intelligence (AI) and genetics and molecular biology data science team to curate the thousands of isolates (strains) now known as existing in both the HIV virus and the SARS-CoV-2 virus. This process will allow us to identify conserved, immutable targets against which monoclonal antibodies are to be produced.”

Our FDA Approval Calendar and other biotech stock resources READ MORE
Copy and paste to browser may be required

Traders News Source LLC (TNS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering small and micro-cap equity markets. TNS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE, NASDAQ, and OTC exchanges. The other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
TNS LLC has not been compensated; directly or indirectly; for producing or publishing this document.
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a chartered financial analyst, for further information on analyst credentials, please email TNS LLC provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written, and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author per the procedures outlined by TNS. TNS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents, or reports. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
TNS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake, or shortcoming. No liability is accepted whatsoever for any direct, indirect, or consequential loss arising from the use of this document. TNS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, TNS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness, or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither TNS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer be featured on our coverage list, contact us via email at:
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Traders News Source


Northwest Biotherapeutics (QB) (USOTC:NWBO)
Historical Stock Chart
From Jul 2022 to Aug 2022 Click Here for more Northwest Biotherapeutics (QB) Charts.
Northwest Biotherapeutics (QB) (USOTC:NWBO)
Historical Stock Chart
From Aug 2021 to Aug 2022 Click Here for more Northwest Biotherapeutics (QB) Charts.